
Opinion|Videos|April 10, 2025
Operationalizing TAR-200 and Other Delivery Systems in Practice
Experts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices?
- What challenges do you anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5


















